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CONTEXT: Understanding and improving the quality of
medication management is particularly important in
the context of the Medicare prescription drug benefit
that took effect last January 2006.
OBJECTIVE: To determine the prevalence of physician–
patient dialogue about medication cost and medication
adherence among elderly adults nationwide.
DESIGN: Cross-sectional survey.
PARTICIPANTS: National stratified random sample of
community-dwelling Medicare beneficiaries aged 65
and older.
MAIN OUTCOME MEASURES: Rates of physician–
patient dialogue about nonadherence and cost-related
medication switching.
RESULTS: Forty-one percent of seniors reported taking
five or more prescription medications, and more than
half has 2 or more prescribing physicians. Thirty-two
percent overall and 24% of those with 3 or more chronic
conditions reported not having talked with their doctor
about all their different medicines in the last 12 months.
Of seniors reporting skipping doses or stopping a
medication because of side effects or perceived nonef-
ficacy, 27% had not talked with a physician about it. Of
those reporting cost-related nonadherence, 39% had
not talked with a physician about it. Thirty-eight
percent of those with cost-related nonadherence
reported switching to a lower priced drug, and in a
multivariable model, having had a discussion about
drug cost was significantly associated with this switch
(odds ratio [OR] 5.04, 95% confidence interval [CI] 4.28–
5.93, P<.001).
CONCLUSIONS: We show that there is a communica-
tion gap between seniors and their physicians around
prescription medications. This communication problem
is an important quality and safety issue, and takes on
added salience as physicians and patients confront new
challenges associated with coverage under new Medi-
care prescription drug plans. Meeting these challenges
will require that more attention be devoted to medica-
tion management during all clinical encounters.
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INTRODUCTION
Seniors who need prescription medications face several chal-
lenges. Rates of chronic illness are increasing.
1 Not surpris-
ingly, prescription drug costs are rising too, outpacing
inflation.
2–4 Data from a number of sources suggest that
seniors often receive poor quality medication management.
Problems include relatively high rates of preventable adverse
drug events,
5 failures to appropriately prescribe and monitor
indicated medications,
6 and frequent use of drugs considered
inappropriate for elderly patients.
7,8 Recent work shows that
cost-related nonadherence with prescriptions is a large and
growing problem.
9–12
Timely and focused physician–patient communication will
be required to address these cost and quality challenges, but
relatively little is known about physician–patient communica-
tion about prescription medications. Some recent studies
suggest that physicians and patients often do not discuss
medication costs,
13,14 but the generalizability of these findings
to seniors in the United States, particularly low-income
seniors, is not known. Understanding the extent of dialogue
between seniors and their physicians about medications and
medication adherence is essential, particularly in light of the
new Medicare drug benefit (Medicare Part D) that was imple-
mented in January of 2006. Whereas the benefit should help
seniors better afford prescription medications,
15 it is also likely
to create new problems. Among these are the need to change
medication regimens as prescription drug plan (PDP) formu-
laries change, or when seniors change plans, and challenges
posed by the “donut hole” (many seniors will be responsible for
100% of drug costs between $2,250 and $5,100 of total
costs).
16 Negotiating these and other medication-related issues
will be a tremendous communications challenge for seniors
and their health care providers.
17
To better understand the frequency with which seniors and
their physicians communicate about medication costs and
medication adherence, we surveyed 17,000 community-
dwelling Medicare beneficiaries 65 years and older in all 50
states, over those residing in low-income neighborhoods. This
paper has two main objectives. First, we describe rates at which
Medicare beneficiaries discuss nonadherence and cost-related
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6nonadherence with a doctor. Second, to evaluate the clinical
impact of physician–patient dialogue about medication costs,
we analyze the relationship between physician–patient dialogue
about medication costs and switching to lower cost medicines.
METHODS
Patients
Data for sampling were provided by the Centers for Medicare
and Medicaid Services (CMS). For each state, CMS provided a
1% probability sample of noninstitutionalized Medicare bene-
ficiaries aged 65 or older. To identify high-poverty neighbor-
hoods, we linked the CMS file to the 2000 U.S. Census data
through geocoding. This involved using 9-digit ZIP codes to
assign individuals to specific census block groups. We defined
high-poverty neighborhoods as those in which 13% or more of
residents age 65 and older had incomes below 100% of the
federal poverty level using the 2000 Census classifications. We
then sampled from three strata (1) beneficiaries with full
Medicaid benefits, (2) beneficiaries without Medicaid benefits
who reside in a high-poverty neighborhood, and (3) beneficia-
ries without Medicaid benefits who do not reside in a high-
poverty neighborhood. In each state, we randomly sampled
from within each stratum, with a fixed allocation from each,
over sampling Medicaid enrollees and seniors in low-income
neighborhoods. The starting sample included 36,901 Medicare
beneficiaries. The Tufts–New England Medical Center institu-
tional review board approved all protocols.
Data Collection
We administered the survey in English and Spanish between
July and October of 2003 using a standard 5-stage mail and
telephone survey protocol,
18 with a response rate of 51% (N=
17,569). Compared with respondents, nonrespondents were
slightly older (76.3 vs 74.9 years, P<.001), less likely to be
white (82.6% vs 88.0%, P<.001), and more likely to have
Medicaid (10.9% vs 6.1%). Mean family income in census block
groups from which beneficiaries were sampled was $54,540 for
respondents and $53,350 for nonrespondents (P=.01). There
were no differences in sex or HMO membership (P>.05).
Variables
The survey instrument focused on prescription drug coverage,
drug use, and out-of-pocket spending on drugs. It also
included additional questions on health status, income, and
sociodemographic characteristics. To assess chronic disease
burden, we asked patients whether they had ever been told by
a doctor that they had hypertension, heart attack, congestive
heart failure, asthma/emphysema/COPD, diabetes, rheuma-
toid or osteoarthritis, cancer, or depression.
19 Approximately
10% of respondents were missing income data, and for these
income was imputed using Buck’s method.
20 We used a 6-item
subset of the Medical Outcomes Study Short Form 36-item
Survey to measure health status, and calculated physical
component and mental component summary scores.
21
All adherence questions referenced experiences over the
past 12 months. Factor analysis confirmed our conceptual
model of 3 types of nonadherence: (1) cost-related nonadher-
ence, (2) nonadherence because of medication experiences
(e.g., side effects); and (3) nonadherence because of self-
assessed need for particular medications. A summary indica-
tor of “any nonadherence” was defined to denote nonadherence
in one or more of these areas.
We evaluated cost-related nonadherence with questions
about the following 3 behaviors: not filling a prescription
because of cost, skipping doses to make a prescription last
longer, and taking smaller doses than prescribed to make a
prescription last longer (see Appendix for exact wording). We
assessed experience-related nonadherence by asking whether
the respondent had skipped doses or stopped taking a
medicine because it was making them feel worse and/or they
did not think the medicine was helping them. We assessed
nonadherence because of self-assessed needs by asking
whether respondents had failed to fill a prescription because
they felt they were taking too many medicines and/or they did
not think they needed the medicine.
To understand physician–patient dialogue about medica-
tions and medication nonadherence, we asked participants if
their doctors had asked them about all of the different
medications they were using, if they had talked with any of
their doctors about the cost of their prescription medications,
and if they had talked with any of their doctors about changing
one of their prescription medicines because it was making
them feel worse or was not working. In addition, we asked
whether any of their doctors had switched them from one
prescription medicine to a different one that would cost them
less (see Appendix).
Analyses
To understand how medication nonadherence and physi-
cian–patient dialogue about nonadherence are related to
beneficiaries’ clinical complexity, we determined rates of
different types of medication nonadherence, rates of physi-
cian–patient dialogue about nonadherence, and rates of
switching to lower cost medicines for those with 0, 1, 2,
and 3 or more chronic conditions. To assess the statistical
significance of trends in responses by number of chronic
conditions, we used logistic regression to regress each
dependent variable on the chronic disease variable, which
takes a value from 0 to 3, and tested the coefficient with a
likelihood ratio (chi-square) test.
We examined rates of physician–patient dialogue in the
following subgroups: no nonadherence, any nonadherence,
any cost-related nonadherence, number of types of cost-
related nonadherence (1, 2, or 3), and nonadherence because
of experiences. Using t tests, we compared rates of physician–
patient dialogue about medication costs between those with
and without cost-related nonadherence, and among those with
1, 2, and 3 types of cost-related nonadherence; physician–
patient dialogue about skipping or stopping because the
beneficiary felt worse or the medicine was not helping in those
who did and did not report this type of nonadherence; and
rates of switching to lower cost medications among those with
and without cost-related nonadherence.
We used multivariable logistic regression to determine
whether having had a discussion about medication costs was
associated with switching to a lower cost medication. Covari-
ates included clinical characteristics (disease count, number of
prescription medications, and number of different types of
7 Wilson et al.: Communication About Prescription Medications JGIMcost-related nonadherence), sociodemographic characteristics
(age, sex, marital status, education, and race), health variables
(physical and mental component scores from the 6-item Short-
Form Health Survey), physician–patient relationship quality
measures (duration of physician–patient relationship and
whether the patient felt the doctor usually spent enough time
with them during visits), and economic variables (income,
prescription drug coverage, and out-of-pocket costs for pre-
scription medications). We used the missing indicator method
to account for missing values.
22 Prescription drug coverage
was not included in the final model because it was highly
collinear with having a discussion about medication costs.
Those without drug coverage were much more likely to talk
about cost, so models that included both variables resulted in
an uninterpretable beta coefficient for drug coverage.
We weighted all analyses to account for sampling and design
factors. Probability sampling weights were applied to all ana-
lyses to correct for unequal sampling probabilities across states
and strata. The statistical software used (STATA 7.0) takes these
weights into account when computing standard errors.
RESULTS
Sociodemographic Characteristics
and Medication Use
Seniors’ mean age was 74.9 years, 58.7% were female, 12.0%
were nonwhite, and 27.3% had no prescription drug coverage
(Table 1). Thirty-two percent reported 3 or more chronic
conditions and 41.0% used 5 or more prescriptions. Of those
on 1 or more medications, 53.6% had 2 or more prescribing
physicians and 35.7% used 2 or more pharmacies. Thirty-two
percent of spent more than $100 per month out of pocket for
prescription medications.
Nonadherence and Dialogue
About Nonadherence
Forty percent of beneficiaries reported some kind of nonadher-
ence, including 26.3% with some type of cost-related non-
adherence and 28.2% nonadherence not related to cost
(Table 2). Two thirds (68.2%) reported that they had, in the
last 12 months, talked with their doctor about all of the
different medications they use, but only about one third
(30.9%) had discussed medication costs with a doctor.
Medication nonadherence increased linearly for all types of
nonadherence as the number of chronic conditions increased
(P<.001). For simplicity, Table 2 shows only rates for those
with 3 or more chronic conditions. Among those with 3 or more
chronic conditions, 52.1% reported medication nonadherence
of some kind, including 34.9% with cost-related nonadher-
ence. Similarly, rates of dialogue between patients and physi-
cians increased linearly as the number of chronic conditions
increased (Table 2, P<.001 for trend for all rows in the table).
However, despite this trend, fully 24% of those with 3 or more
chronic conditions had not talked with their personal doctor
about all of the different medicines they were using in the last
12 months. As context, 71% of patients with 3 or more chronic
conditions were taking 5 or more medications, and 67%
received medications from 2 or more physicians (data not
shown).
Rates of physician–patient dialogue among those reporting
different types of medication nonadherence are shown in
Table 3. Column 1 examines dialogues about changing a
medicine because it was making them feel worse or was not
working. Of those with this type of nonadherence, 72.9% had
talked with a physician about it, leaving 27.1% who had not.
Column 2 of Table 3 shows rates of dialogues about medication
costs. Of those reporting any cost-related nonadherence,
61.0% had talked with a physician about it, leaving 39.0%
who had not. Of those reporting 3 types of cost-related
nonadherence, 78.4% had talked with a physician about it,
leaving 21.6% who had not.
Switching to a Lower Cost Medication
Column 3 of Table 3 examines rates at which patients were
switched to lower costing medications. In the full sample,
Table 1. Sample Characteristics
Characteristic Total
Age (mean (SD), median 74.9 (7.0), 74
Sex (% female) 58.7
Race (% white) 88.0
Education (% less than high school) 25.2
Income per month (%)
<$700 9.1
$700–1,000 14.9
$1,001–2,000 33.2
>$2,000 42.9
Prescription drug coverage (% with none) 27.3
Duration of physician–patient relationship (%)
Less than 1 year 10.9
1 to 5 years 38.4
More than 5 years 50.7
Number of chronic conditions
0 12.5
1 27.8
2 27.2
3 or more 32.5
Number of medications (%)
0 11.0
1–2 22.8
3–4 25.2
5 or more 41.0
Those on 1 or more medication
Medication types (%)
Pills 97.6
Injections 9.0
Inhalers 16.9
Eye drops 16.3
Creams 14.0
Number of prescribing physicians (%)
1 46.4
2 or more 53.6
Number of pharmacies (%)
1 64.3
2 or more 35.7
Monthly prescription drug costs, mean $ (SD) median 111 (133), 63
0 9.1%
<$20 16.8%
$21–50 19.5%
$51–75 13.0%
$76–100 10.1%
$101–300 23.7%
>$300 7.8%
We applied sampling weights to all results to correct for difference in
sampling probabilities across the strata. The observed sample size was
17,569, of which 15,445 were on one or more medications.
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cost medication in the last 12 months. Nearly 40% (38.1%) of
those with any cost-related nonadherence, and over half
(51.1%) of those with 3 types of cost-related nonadherence
had been switched to a lower cost medication.
Multivariable analyses showed that having had a discussion
about medication cost was strongly associated with switching
to a lower cost medication (Table 4, odds ratio [OR] 5.04, 95%
confidence interval [CI] 4.28–5.93, P<.001). Of those who
reported a physician–patient discussion about cost, 41% had
switched to a lower cost medication, compared to 12% for
those who did not have such a discussion. Having 2 or more
chronic conditions (OR 1.66, 95% CI 1.40–1.98, P<.001),
taking 2 or more prescription medications (OR 1.44, 95% CI
1.13–1.83), and exhibiting more different types of cost-related
nonadherence (OR 1.38, 95% CI 1.11–1.70; P=.004 for 1 type
compared to none; OR 1.48, 95% CI 1.14–1.93, P<.004 for 2
types compared to none; and OR 2.05, 95% CI 1.57–2.67,
P<.001 for 3 types compared to none) were also independently
associated with switching to a lower cost medication.
DISCUSSION
This study had three important findings. First, 27% of seniors
who skipped doses or stopped taking a medicine because of
side effects or poor perceived efficacy did not tell their
physician. Second, 39% of seniors who reported cost-related
nonadherence had not talked with their physicians about it.
Third, physician–patient dialogue about medication costs was
associated with patients’ being switched to lower cost medications.
Recent data suggest that patients often do not report
medication-related symptoms to physicians, and that physi-
cians do not always respond when they do.
23,24 We show that
this problem is widespread among U.S. elderly. The confluence
of the factors we describe—multiple chronic conditions, use of
numerous medications, a variety of prescribing physicians,
lack of regular review of medications, and poor communication
about medication side effects and perceived efficacy—places
seniors at risk for both suboptimal clinical outcomes and
adverse drug events. We believe that it is important for
Table 2. Medication Nonadherence and Physician–patient
Dialogue (All Items Refer to the Last 12 Months)
Total 3+
Chronic
conditions
(35.2%)*
Rates of medication nonadherence (%)
Any nonadherence
†
- 40.1 52.1
Any cost-related nonadherence 26.3 34.9
Not filling prescription because of cost 18.3 24.9
Skipping doses to make prescription last
longer
15.8 21.8
Taking a smaller dose to make prescription
last longer
12.4 18.5
Any nonadherence not related to cost 28.2 37.4
Nonadherence because of experiences
‡ 24.4 33.8
Nonadherence because of self-assessed
need
‡
14.5 18.8
Physician–patient dialogue (% yes)
Did your doctor talk with you about all your
medicines?
68.2 75.8
Did you talk with any of your doctors about
prescription medicine costs?
30.9 41.3
Did you talk with any of your doctors about
changing a medicine because it was making
you feel worse or was not working?
28.9 41.9
We applied sampling weights to all results to correct for difference in
sampling probabilities across the strata. The total observed sample size
was 17,569, of which 5,739 had 3 or more chronic conditions.
*For each row, we examined the trend for 0, 1, 2, and 3 or more chronic
conditions, and for each the trend was significant, P<.001. For simplicity,
we present only the rates for 3 or more conditions.
†“Any cost-related nonadherence” refers to beneficiaries who reported
nonadherence on any of the cost or noncost items (items 1–3 and 5–8i n
the Appendix).
‡These rows each summarize 2 survey items.
Table 3. Rates of Physician–patient Dialogue About Medication
Nonadherence Among those with Different Types of
Nonadherence
Type of reported
prescription
medication
nonadherence
(%)
During the last 12 months, was there
physician–patient dialogue about:
(1)
Changing a
medicine
because it
was making
you feel worse
or was
not working?
(% yes)
(2)
Medication
costs? (%
yes)
(3) Did any
of your
doctors
switch you to
a different
one that
would cost
less? (% yes)
Full sample 28.9 30.9 22.3
Taking medication
as prescribed (no
nonadherence,
60.0%)
13.4* 17.9* 14.1*
Any medication
nonadherence
(40.0%)
51.9 50.4 34.7
Any cost-related
nonadherence
(26.3%)
– 61.0 38.1
Number of types of
cost-related
nonadherence
†
-
–
1 (12.8%) – 51.0 31.7
2 (7.1%) – 62.8 38.5
3 (6.1%) – 78.4 51.1
Nonadherence
because of
experiences
(skipped doses or
stopped taking
because of side
effects/not
helping, 24.4%)
72.9 –
‡ –
We applied sampling weights to all results to correct for difference in
sampling probabilities across the strata. The total observed sample size
was 17,569.
*Compared with the row “taking medication as prescribed (no medication
nonadherence),” all subsequent rows were statistically significantly
different (P<.001 for all).
†The three types of cost-related nonadherence were not filling a
prescription because of cost, skipping doses to make a prescription last
longer, and taking smaller doses than prescribed to make a prescription
last longer.
‡The empty cells in the table are cases for which the cross-tabulation is
not applicable. For example, it is not meaningful to show the rate of cost-
related dialogue among those who skipped doses or stopped taking
because of side effects/not helping.
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adherence and problems paying for medications, and for patients
to routinely volunteer such information, even if not asked.
We
10,12,25 and others
9 have previously shown that cost-
related medication nonadherence is common among seniors.
However, only 2 studies have examined physician–patient
dialogue about cost-related nonadherence. Alexander et al.
14
found that although physicians and patients are willing to
discuss medication costs, only 35% of physicians and 15% of
patients report doing so. Piette et al.
13 conducted an online
survey of persons over age 50 participating in a web-based
consumer information and marketing network, and found that
35% of those reporting cost-related nonadherence had not
discussed it with their physician. The rates of physician–
patient dialogue about cost-related medication nonadherence
that we report are similar to those found by Piette et al.,
13 but
we sampled Americans 65 years and older in all 50 states, and
sampled seniors from low-income neighborhoods, making our
results generalizable to community-dwelling elderly nationwide.
The finding that physician–patient dialogue about costs was
associated with switches to lower cost medications suggests that
such discussions are worth having. Many of these switches may
have been generic substitutions and others may have been
therapeutic substitutions. Whereas patients sometimes do not
want to be changed to generic drugs,
26–28 the FDA guarantees
the therapeutic equivalence of generics
29 and generic substitu-
tion is a safe way to reduce costs. Physicians have a number of
other cost-reducing strategies at their disposal, including
within-class drug switches, between-class drug switches, dose
reductions, and use of samples. In addition, physicians can help
patients prioritize which medications are most important and
help design safe and effective, or at least optimal, alternative
strategies. None of these strategies, however, can be implemen-
ted if physicians and patients are not routinely discussing
medication use and medication costs.
There are several study limitations. Our response rates were
lower than anticipated, and respondents were more likely than
nonrespondents to be white and to have higher incomes. Piette
et al.
13 found that neither race nor income was associated with
physician–patient adherence-dialogue, and we do not suspect
that nonresponse biased our analytic findings. Because of
social desirability effects (the desire not to admit socially
undesirable behaviors such as nonadherence), the levels of
nonadherence and dialogue about nonadherence that we
report may underestimate true levels. Finally, given the
cross-sectional nature of our data, we cannot definitively know
the temporal ordering of events related to medication discus-
sions and switching to lower cost medications. It is possible
that in some cases, a switch leads to medication discussion
rather than the reverse. A longitudinal study design would be
needed to verify the sequencing of these effects.
In conclusion, the suboptimal physician–patient communi-
cation about medications identified in this study is an impor-
tant clinical backdrop against which the new Medicare drug
benefit will be implemented. Prescription drug plans will have to
employ similar cost-containment techniques to those currently
used by commercial health insurance plans, including formu-
laries, premiums, deductibles, copays, and drug tiers. Physi-
cians will need to work closely with seniors and their families to
identify clinically appropriate substitutes if available plans do
not cover the drugs patients are currently using. Whereas
collaboration with pharmacists may be useful because of a
paucity of well-designed studies, relatively little is known about
the effectiveness of this strategy.
30–32 These and other chal-
lenges will require not only that physicians and patients
educate themselves about the new drug benefit and coverage
rules of the new Medicare PDPs, but will also require that
substantial time and effort be dedicated to physician–patient
communication about medication management.
Early experiences with Part D have been mixed.
33 With
technical problems caused problems with the automatic
enrollment of some dual eligibles (those eligible for both
Medicaid and Medicare) into PDPs,
34 there have been reports
of seniors being unable to obtain key medications.
35,36 Early
anecdotal reports suggest that seniors are using a variety of
sources to obtain information and for informed decision
making, including calling Medicare, surfing the internet, and
asking relatives, friends, pharmacists, and health care provi-
ders.
17 However, with these challenges come new opportuni-
ties. It should be possible for plans to use pharmacy claims to
inform physicians about patients’ medication use and adher-
ence. For example, drug plans could provide physicians with
both medication lists and refill rates in the hopes of triggering
more timely and effective discussions about coping with
complex drug regimens.
These findings paint a sobering picture of prescription
medication taking for America’s seniors. Most seniors have
multiple chronic diseases, take multiple prescription medica-
tion, have more than one prescribing physician, and use
multiple pharmacies. In these circumstances the need for
improved physician–patient communication about medications
is pressing. Technology aimed at improving the accuracy and
timeliness of medication information, such as electronic med-
ical records and electronic prescribing, can support the efforts
of physicians and patients in this effort. But more and better
talk is urgently needed. Quality measurement and quality
improvement initiatives that focus on prescription-medica-
tion-related communication might speed progress in this area.
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Table 4. Significant Multivariable Correlates of Switching to Another
Medication that Would Cost Less (Odds Ratios [P Values])
Variable Odds ratio (95% CI) P value
2 or more chronic conditions 1.66 (1.40–1.98) <0.001
2 or more prescription medications 1.44 (1.13–1.83)
Number of types of cost related
nonadherence
None Reference –
1 1.38 (1.11–1.70) 0.004
2 1.48 (1.14–1.93) 0.004
3 2.05 (1.57–2.67) <0.001
Discussion about cost (1=yes, 0=no) 5.04 (4.28–5.93) <0.001
Nonsignificant covariates included age, sex, education, marital status,
race, physical health, mental health, number of prescription medications,
income, out-of-pocket medication costs, duration of physician–patient
relationship, and whether the patient felt the physician spends enough
time with them during office visits.
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APPENDIX
Medication adherence items (response options for 2–8 were
yes, often; yes, sometimes; and no, never).
1. During the last 12 months, how many times did you
decide not to fill a prescription because it was too
expensive? Response options were none, 1 time, 2 times,
3–4 times, 5–9 times, 10 or more times.
2. During the last 12 months, have you skipped doses of a
medicine to make the prescription last longer?
3. During the last 12 months, have you taken a smaller dose
of medicine so that the prescription would last longer (for
example, by cutting pills in half)
4. During the last 12 months, have you spent less on food,
heat, or other basic needs so that you would have enough
money for your medicines?
5. During the last 12 months, did you decide not to fill a
prescription because you felt you were taking too many
medications?
6. During the last 12 months, did you decide not to fill a
prescription because you didn’tt h i n ky o uneeded the
medicine?
7. During the last 12 months, have you skipped doses or
stopped taking a medicine because it was making you feel
worse?
8. During the last 12 months, have you skipped doses or
stopped taking a medicine because you didn’t think it was
helping you?
Physician–patient dialogue items (response options were yes
and no).
1. During the last 12 months, did your personal doctor talk
with you about all of the different medicines you are using,
including medicines prescribed by other doctors?
2. During the last 12 months, did you talk with any of your
doctors about the cost of your prescription medicines?
3. During the last 12 months, did you talk with any of your
doctors about changing one of your prescription medicines
because the medicine was making you feel worse or was
not working?
4. During the last 12 months, did any of your doctors switch
you from one prescription medicine to a different one that
would cost you less?
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